Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil.

Journal: Applied health economics and health policy

Volume: 16

Issue: 5

Year of Publication: 2019

Affiliated Institutions:  Department of Social Pharmacy, College of Pharmacy, Federal University of Minas Gerais, Av. Presidente Antônio Carlos, , Campus Pampulha, Belo Horizonte, MG, -, Brazil. SUS Collaborating Centre-Technology Assessment and Excellence in Health (CCATES/UFMG), College of Pharmacy, Federal University of Minas Gerais, Av. Presidente Antônio Carlos, , Campus Pampulha, Belo Horizonte, MG, -, Brazil. Department of Preventive and Social Medicine, College of Medicine, Federal University of Minas Gerais, Av. Prof. Alfredo Balena, , Santa Efigênia, Belo Horizonte, MG, -, Brazil. WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy. Strathclyde Institute of Pharmacy and Biomedical Sciences, Strathclyde University, Glasgow, G RE, United Kingdom. Strathclyde Institute of Pharmacy and Biomedical Sciences, Strathclyde University, Glasgow, G RE, United Kingdom. brian.godman@strath.ac.uk.

Abstract summary 

Schizophrenia is associated with significant economic burden. In Brazil, antipsychotic drugs and outpatient and hospital services are provided by the Brazilian National Health System (SUS) for patients with schizophrenia. However, few studies capture the cost of managing these patients within the Brazilian NHS. This is important to appraise different management approaches within universal healthcare systems.Our objective was to use real-world data to describe the costs associated with the treatment of schizophrenia in adults receiving atypical antipsychotics in Brazil from 2000 to 2010.We integrated three national databases for adult patients with schizophrenia receiving one or more atypical antipsychotics. We assessed only direct medical costs and the study was conducted from a public-payer perspective. A multivariate log-linear regression model was performed to evaluate associations between costs and clinical and demographic variables.We identified 174,310 patients with schizophrenia, with mean ± standard deviation (SD) annual costs of $US1811.92 ± 284.39 per patient. Atypical antipsychotics accounted for 79.7% of total costs, with a mean annual cost per patient of $US1578.74 ± 240.40. Mean annual costs per patient were $US2482.90 ± 302.92 for psychiatric hospitalization and $US862.96 ± 160.18 for outpatient psychiatric care. Olanzapine was used by 47.7% of patients and represented 62.8% of the total costs of atypical antipsychotics. Patients who used clozapine had the highest mean annual cost per patient for outpatient psychiatric care and psychiatric hospitalization.Atypical antipsychotics were responsible for the majority of the schizophrenia treatment costs, and psychiatric hospitalization costs were the highest mean annual cost per patient. Authorities should ensure efficient use of atypical antipsychotics and encourage outpatient psychiatric care over psychiatric hospitalization where possible.

Authors & Co-authors:  Barbosa Wallace Breno WB Costa Juliana de Oliveira JO de Lemos Lívia Lovato Pires LLP Gomes Rosângela Maria RM de Oliveira Helian Nunes HN Ruas Cristina Mariano CM Acurcio Francisco de Assis FA Barbui Corrado C Bennie Marion M Godman Brian B Guerra Augusto Afonso AA

Study Outcome 

Source Link: Visit source

Statistics
Citations :  American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 5. Arlington: American Psychiatric Association; 2013.
Authors :  11
Identifiers
Doi : 10.1007/s40258-018-0408-4
SSN : 1179-1896
Study Population
Male,Female
Mesh Terms
Adolescent
Other Terms
Study Design
Cohort Study,Cross Sectional Study
Study Approach
Country of Study
Publication Country
New Zealand